Losartan potassium and Decreased immune responsiveness - a phase IV clinical study of FDA data
Decreased immune responsiveness is found among people who take Losartan potassium, especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years.
The phase IV clinical study analyzes which people take Losartan potassium and have Decreased immune responsiveness. It is created by eHealthMe based on reports of 35,672 people who have side effects when taking Losartan potassium from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
35,672 people reported to have side effects when taking Losartan potassium.
Among them, 34 people (0.1%) have Decreased immune responsiveness.
What is Losartan potassium?
Losartan potassium has active ingredients of losartan potassium. It is often used in high blood pressure. eHealthMe is studying from 37,027 Losartan potassium users for its effectiveness, alternative drugs and more.
What is Decreased immune responsiveness?
Decreased immune responsiveness is found to be associated with 1,159 drugs and 658 conditions by eHealthMe.
Number of Losartan potassium and Decreased immune responsiveness reports submitted per year:
Time on Losartan potassium when people have Decreased immune responsiveness *:
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 100 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Decreased immune responsiveness when taking Losartan potassium *:
- female: 70.59 %
- male: 29.41 %
Age of people who have Decreased immune responsiveness when taking Losartan potassium *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 4.17 %
- 40-49: 4.17 %
- 50-59: 4.17 %
- 60+: 87.5 %
Common drugs people take besides Losartan potassium *:
- Ibrance: 7 people, 20.59%
- Acetaminophen: 5 people, 14.71%
- Enbrel: 5 people, 14.71%
- Glivec: 5 people, 14.71%
- Penicillamine: 4 people, 11.76%
- Azithromycin: 4 people, 11.76%
- Calcium: 4 people, 11.76%
- Celebrex: 4 people, 11.76%
- Combivent: 4 people, 11.76%
- Hydrochlorothiazide: 4 people, 11.76%
Common side effects people have besides Decreased immune responsiveness *:
- Fatigue (feeling of tiredness): 12 people, 35.29%
- Pain: 11 people, 32.35%
- Nausea (feeling of having an urge to vomit): 11 people, 32.35%
- Joint Pain: 11 people, 32.35%
- Headache (pain in head): 10 people, 29.41%
- Weakness: 9 people, 26.47%
- Asthma: 8 people, 23.53%
- Constipation: 8 people, 23.53%
- Dizziness: 8 people, 23.53%
- Nasopharyngitis (inflammation of the nasopharynx): 7 people, 20.59%
Common conditions people have *:
- Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 11 people, 32.35%
- Pain: 10 people, 29.41%
- Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 5 people, 14.71%
- Impaired Healing: 4 people, 11.76%
- Gastrointestinal Disorder (functional problems of gastrointestinal tract): 4 people, 11.76%
- Asthma: 4 people, 11.76%
- Breast Cancer Metastatic: 4 people, 11.76%
- Nasopharyngitis (inflammation of the nasopharynx): 4 people, 11.76%
- Joint Pain: 4 people, 11.76%
- Upper Respiratory Tract Infection: 4 people, 11.76%
* Approximation only. Some reports may have incomplete information.
Do you take Losartan potassium and have Decreased immune responsiveness?Check whether Decreased immune responsiveness is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Lai SW, Lin HF, Lin CL, Liao KF, "No association between losartan use and acute pancreatitis in hypertensive patients", Eur J Hosp Pharm, 2017 Mar .
Alternative drugs to, pros and cons of Losartan potassium:
- Losartan potassium (37,027 reports)
Decreased immune responsiveness treatments and more:
- Decreased immune responsiveness (7,208 reports)
COVID vaccines that are related to Decreased immune responsiveness:
- Decreased immune responsiveness in Moderna COVID Vaccine
- Decreased immune responsiveness in Pfizer BioNTech Covid Vaccine
- Decreased immune responsiveness in Johnson and Johnson Covid Vaccine
How severe was Decreased immune responsiveness and when was it recovered:
Expand to all the drugs that have ingredients of losartan potassium:
Common drugs associated with Decreased immune responsiveness:
All the drugs that are associated with Decreased immune responsiveness:
- Decreased immune responsiveness (1,159 drugs)
Common conditions associated with Decreased immune responsiveness:
All the conditions that are associated with Decreased immune responsiveness:
- Decreased immune responsiveness (658 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on losartan potassium (the active ingredients of Losartan potassium) and Losartan potassium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Perindopril Erbumine and Terbinafine Hydrochloride drug interaction - 10 seconds ago
- Meridia and Famotidine drug interaction - 11 seconds ago
- Afinitor and Self Injurious Behavior - 13 seconds ago
- Nitrol and Epidermal Necrolysis - 17 seconds ago
- Omega-3 Marine Triglycerides and Coreg drug interaction - 20 seconds ago